跳轉至內容
Merck
  • Notch pathway inhibition controls myeloma bone disease in the murine MOPC315.BM model.

Notch pathway inhibition controls myeloma bone disease in the murine MOPC315.BM model.

Blood cancer journal (2014-06-14)
R Schwarzer, N Nickel, J Godau, B M Willie, G N Duda, R Schwarzer, B Cirovic, A Leutz, R Manz, B Bogen, B Dörken, F Jundt
摘要

Despite evidence that deregulated Notch signalling is a master regulator of multiple myeloma (MM) pathogenesis, its contribution to myeloma bone disease remains to be resolved. Notch promotes survival of human MM cells and triggers human osteoclast activity in vitro. Here, we show that inhibition of Notch through the γ-secretase inhibitor XII (GSI XII) induces apoptosis of murine MOPC315.BM myeloma cells with high Notch activity. GSI XII impairs murine osteoclast differentiation of receptor activator of NF-κB ligand (RANKL)-stimulated RAW264.7 cells in vitro. In the murine MOPC315.BM myeloma model GSI XII has potent anti-MM activity and reduces osteolytic lesions as evidenced by diminished myeloma-specific monoclonal immunoglobulin (Ig)-A serum levels and quantitative assessment of bone structure changes via high-resolution microcomputed tomography scans. Thus, we suggest that Notch inhibition through GSI XII controls myeloma bone disease mainly by targeting Notch in MM cells and possibly in osteoclasts in their microenvironment. We conclude that Notch inhibition is a valid therapeutic strategy in MM.

材料
產品編號
品牌
產品描述

Sigma-Aldrich
磷酸酶底物, 5 mg tablets
Sigma-Aldrich
4-硝基苯基磷酸盐 二钠盐 六水合物, suitable for enzyme immunoassay, ≥99.0% (enzymatic)
Sigma-Aldrich
4-硝基苯基磷酸盐 二钠盐 六水合物, tablet
Sigma-Aldrich
4-硝基苯基磷酸盐 二钠盐 六水合物, powder, BioReagent, suitable for cell culture, ≥97%
Sigma-Aldrich
4-硝基苯基磷酸盐 二钠盐 六水合物, tablet
Sigma-Aldrich
磷酸酶底物, powder
Sigma-Aldrich
4-硝基苯基磷酸盐 二钠盐 六水合物, tablet
Sigma-Aldrich
磷酸酶底物, 40 mg tablets
Sigma-Aldrich
磷酸酶底物, 100 mg capsules
Sigma-Aldrich
磷酸酶底物, 40 mg capsules
Sigma-Aldrich
磷酸酶底物, Suitable for manufacturing of diagnostic kits and reagents